Market Cap : 16.26 B | Enterprise Value : 13.67 B | PE Ratio : 17.21 | PB Ratio : 3.97 |
---|
NAS:INCY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:INCY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Incyte's enterprise value is $13,672 Mil. Incyte's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $694 Mil. Therefore, Incyte's EV-to-EBITDA for today is 19.69.
The historical rank and industry rank for Incyte's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Incyte was 2618.50. The lowest was -1585.57. And the median was 22.38.
INCY's EV-to-EBITDA is ranked worse thanEV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-18), Incyte's stock price is $73.44. Incyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $4.250. Therefore, Incyte's PE Ratio for today is 17.28.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Incyte's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Incyte's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Incyte's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Incyte's EV-to-EBITDA falls into.
Incyte's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 13672.013 | / | 694.445 | |
= | 19.69 |
Incyte's current Enterprise Value is $13,672 Mil.
Incyte's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $694 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Incyte's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 73.44 | / | 4.250 | |
= | 17.28 |
Incyte's share price for today is $73.44.
Incyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.250.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Incyte's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Tray Thomas | officer: Principal Accounting Officer | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Brawley Otis W | director | 5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518 |
High Katherine A | director | 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 |
Harrigan Edmund | director | |
Morrissey Michael James | officer: EVP, Head of Tech. Operations | IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803 |
Dickinson Jonathan Elliott | officer: EVP, General Manager, Europe | CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803 |
Stamoulis Christiana | officer: EVP & Chief Financial Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139 |
Dhanak Dashyant | officer: EVP & Chief Scientific Officer | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Pasquale Maria E | officer: EVP & General Counsel | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Fouse Jacqualyn A | director | C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108 |
Iyengar Vijay K | officer: EVP GPS, BD, & Licensing | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Stein Steven H | officer: EVP & Chief Medical Officer | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Trower Paul | officer: VP, Finance & Prin Acc Officer | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Clancy Paul J | director | C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 |
Bienaime Jean Jacques | director | 925 PAGE MILL ROAD PALO ALTO CA 94304 |
Other Sources
By Zacks 2022-02-09
By Zacks 2022-02-03
By tipranks.com 2022-02-08
By Zacks 2022-01-17
By Zacks 2021-12-02
By Zacks 2021-12-06
By tipranks.com 2022-02-11
By Zacks 2022-02-03
By Zacks 2022-01-10
By Zacks 2022-03-28
By tipranks.com 2022-03-27
By Zacks 2022-03-15
By Zacks 2022-03-16
By tipranks.com 2022-02-10